Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD (NCT01880788) | Clinical Trial Compass
CompletedNot Applicable
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
United States152 participantsStarted 2012-11
Plain-language summary
The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis.
Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced AMD.
Who can participate
Age range30 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Caucasian
* 30 years and older (CSC)
* 50 years and older (Advanced AMD)
* Genders Eligible for Study: Both
* Completed Consent form
* Diagnosis of choroidal neovascularization in at least one eye
Exclusion Criteria:
* Patient age less than 30 years (CSC).
* Patient age less than 50 years (AMD).
* Presence of retinal disease involving the photoreceptors and/or outer retinal layers other than AMD and CSC such as high myopia, retinal dystrophies, retinal vein occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases which have been present prior to the age of 30.
* Opacities of the ocular media, limitations of pupillary dilation or other problems sufficient to preclude adequate fundus photography.
* Missing informed consent
* Previous sample donation under this protocol